Skip to main content
Erschienen in: International Cancer Conference Journal 1/2017

Open Access 24.11.2016 | Video article

Transanal approach for intersphincteric resection of rectal cancer in a patient with a huge prostatic hypertrophy

verfasst von: Yoshiyuki Kiyasu, Kenji Kawada, Kyoichi Hashimoto, Ryo Takahashi, Koya Hida, Yoshiharu Sakai

Erschienen in: International Cancer Conference Journal | Ausgabe 1/2017

Abstract

The gold standard of surgical technique for rectal cancer is total mesorectal excision (TME). Laparoscopic TME has been proven to provide surgical safety and oncological outcomes equivalent to open TME. However, dissection of the lower rectum has some inherent difficulties related to a narrow pelvic space. The challenge of TME in the lower rectum was confirmed by the Colorectal Cancer Laparoscopic or Open Resection (COLOR) II trial showing a 9% positive circumferential margin (CRM) rate in laparoscopic TME and a 22% positive CRM rate in open TME. Recently, transanal TME has attracted intense attention as a promising alternative to laparoscopic TME. In this video article, we show the performance of a transanal approach for intersphincteric resection (ISR) of rectal cancer in a patient with a huge prostatic hypertrophy.
Begleitmaterial
Supplementary material 1 (MP4 96006 kb)
Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1007/​s13691-016-0272-8) contains supplementary material, which is available to authorized users.

Introduction

The gold standard of surgical technique for rectal cancer is total mesorectal excision (TME) [1]. Laparoscopic TME has been proven to provide surgical safety and oncological outcomes equivalent to open TME [2, 3]. However, dissection of the lower rectum has some inherent difficulties related to a narrow pelvic space. The challenge of TME in the lower rectum was confirmed by the Colorectal Cancer Laparoscopic or Open Resection (COLOR) II trial showing a 9% positive circumferential margin (CRM) rate in laparoscopic TME and a 22% positive CRM rate in open TME [2]. Recently, transanal TME has attracted intense attention as a promising alternative to laparoscopic TME [48]. In this video article, we show the performance of a transanal approach for intersphincteric resection (ISR) of rectal cancer in a patient with a huge prostatic hypertrophy.

Case presentation

An 80-year-old man was admitted to our hospital for the treatment of a rectal tumor found incidentally by rectal examination. The tumor, about 3 cm in diameter, was located on the right side of the lower rectum 3 cm above the anal verge. The pathological analysis of the biopsy sample revealed that the tumor was a moderately differentiated adenocarcinoma. Abdominal computed tomography (CT) and magnetic resonance imaging (MRI) indicated that the rectal cancer invaded into the muscularis propria without distant metastases and that lateral pelvic lymph node (LPLN) was not enlarged with a maximum long-axis diameter <3 mm. The most important problem was that the patient had a huge benign prostatic hypertrophy, the size of which was 85 × 80 × 70 mm (Fig. 1a–c). To achieve complete TME with negative CRM, a hybrid transabdominal-transanal approach for ISR was conducted.

Technique

First, vascular division and mobilization of the left colon were performed laparoscopically. The transabdominal approach was continued until the anterior dissection of the rectum became difficult due to a huge prostatic hypertrophy. Next, the circumferential rectal incision and subsequent intersphincteric dissection were performed under direct vision to enable attachment of a single port device (GelPoint Mini; Applied Medical). After closure of the anal orifice, the GelPoint Mini was placed to start the transanal approach. Posterior side of the rectum was first dissected until the transanal approach was connected to the dissection layer made by the transabdominal approach. The dissection procedure was extended to the lateral side. Bilateral pelvic splanchnic nerves were identified at the 5 and 7 o’clock positions. At the anterior side, the proper dissection layer cannot be easily identified because of the perineal body and the enlarged prostate. Once the dissection plane between the rectum and the prostate could be identified, it was relatively easy to continue along the same plane. The assistance provided by the laparoscopic approach was useful to determine the appropriate dissection line in the transanal approach.

Result

The total operative time was 491 min, and the blood loss was 116 ml. Macroscopic findings of the resected specimen showed a solid tumor, 25 × 25 mm in size, and the distal margin was 40 mm (Fig. 2a). On histopathological analysis, the tumor staging was Stage I (pT2N0M0 according to the 7th edition UICC) and the CRM was negative (the free distance of the CRM was 3000 μm) (Fig. 2b). LPLN dissection was not performed, because the indication for LPLN dissection in our institution was defined as LPLN with a short-axis diameter ≥5 mm.

Discussion

Transanal TME is not well-established technically, but it has potential advantages, including superior visualization, facilitation of TME of the lower rectum, and shorter surgical time and less morbidity [48]. The factors that can make transanal TME a preferred approach are (1) male sex, (2) very low location (less than 12 cm from the anal verge), (3) narrow and deep pelvis, (4) visceral obesity (BMI > 30 kg/m2), (5) prostatic hypertrophy, (6) large tumor (>4 cm in diameter), (7) distorted tissue planes due to preoperative radiotherapy, and (8) impalpable, low primary tumor [6]. The hybrid approach composed of both transanal and conventional laparoscopic TME can be an especially appropriate choice for difficult cases, such as a huge tumor occupied within a very narrow pelvic space. In this case, extremely huge prostatic hypertrophy made it difficult to determine the appropriate dissection line of TME, especially on the anterior side of the rectum. Transanal TME with the assistance of the conventional laparoscopic approach is very useful to identify the correct TME plane for rectal cancer patients with prostatic hypertrophy.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interests.

Research involving human participants and/or animals

For this type of study, formal consent is not required.
Written informed consent was obtained from the patient for publication of this Case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of the journal.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

e.Med Innere Medizin

Kombi-Abonnement

Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.

Anhänge

Electronic supplementary material

Below is the link to the electronic supplementary material.
Supplementary material 1 (MP4 96006 kb)
Literatur
1.
Zurück zum Zitat Heald RJ, Ryall RD (1986) Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 1:1479–1482CrossRefPubMed Heald RJ, Ryall RD (1986) Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 1:1479–1482CrossRefPubMed
2.
Zurück zum Zitat Bonjer HJ, Deijen CL, Abis GA, Cuesta MA, van der Pas MH, de Lange-de Klerk ES, Lacy AM, Bemelman WA, Andersson J, Angenete E, Rosenberg J, Fuerst A, Haglind E, COLOR II Study Group (2015) A randomized trial of laparoscopic versus open surgery for rectal cancer. N Engl J Med 372:1324–1332CrossRefPubMed Bonjer HJ, Deijen CL, Abis GA, Cuesta MA, van der Pas MH, de Lange-de Klerk ES, Lacy AM, Bemelman WA, Andersson J, Angenete E, Rosenberg J, Fuerst A, Haglind E, COLOR II Study Group (2015) A randomized trial of laparoscopic versus open surgery for rectal cancer. N Engl J Med 372:1324–1332CrossRefPubMed
3.
Zurück zum Zitat Jeong SY, Park JW, Nam BH, Kim S, Kang SB, Lim SB, Choi HS, Kim DW, Chang HJ, Kim DY, Jung KH, Kim TY, Kang GH, Chie EK, Kim SY, Sohn DK, Kim DH, Kim JS, Lee HS, Kim JH, Oh JH (2014) Open versus laparoscopic surgery for mid-rectal or low-rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): survival outcomes of an open-label, non-inferiority, randomised controlled trial. Lancet Oncol 15:767–774CrossRefPubMed Jeong SY, Park JW, Nam BH, Kim S, Kang SB, Lim SB, Choi HS, Kim DW, Chang HJ, Kim DY, Jung KH, Kim TY, Kang GH, Chie EK, Kim SY, Sohn DK, Kim DH, Kim JS, Lee HS, Kim JH, Oh JH (2014) Open versus laparoscopic surgery for mid-rectal or low-rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): survival outcomes of an open-label, non-inferiority, randomised controlled trial. Lancet Oncol 15:767–774CrossRefPubMed
4.
Zurück zum Zitat Fernández-Hevia M, Delgado S, Castells A, Tasende M, Momblan D, Díaz del Gobbo G, DeLacy B, Balust J, Lacy AM (2015) Transanal total mesorectal excision in rectal cancer: short-term outcomes in comparison with laparoscopic surgery. Ann Surg 261:221–227CrossRefPubMed Fernández-Hevia M, Delgado S, Castells A, Tasende M, Momblan D, Díaz del Gobbo G, DeLacy B, Balust J, Lacy AM (2015) Transanal total mesorectal excision in rectal cancer: short-term outcomes in comparison with laparoscopic surgery. Ann Surg 261:221–227CrossRefPubMed
5.
Zurück zum Zitat Lacy AM, Tasende MM, Delgado S, Fernandez-Hevia M, Jimenez M, De Lacy B, Castells A, Bravo R, Wexner SD, Heald RJ (2015) Transanal total mesorectal excision for rectal cancer: outcomes after 140 patients. J Am Coll Surg 221:415–423CrossRefPubMed Lacy AM, Tasende MM, Delgado S, Fernandez-Hevia M, Jimenez M, De Lacy B, Castells A, Bravo R, Wexner SD, Heald RJ (2015) Transanal total mesorectal excision for rectal cancer: outcomes after 140 patients. J Am Coll Surg 221:415–423CrossRefPubMed
6.
Zurück zum Zitat Motson RW, Whiteford MH, Hompes R, Albert M, Miles WF, Expert Group (2016) Current status of trans-anal total mesorectal excision (TaTME) following the Second International Consensus Conference. Colorectal Dis 8:13–18CrossRef Motson RW, Whiteford MH, Hompes R, Albert M, Miles WF, Expert Group (2016) Current status of trans-anal total mesorectal excision (TaTME) following the Second International Consensus Conference. Colorectal Dis 8:13–18CrossRef
7.
Zurück zum Zitat Hasegawa S, Hida K, Kawada K, Sakai Y (2016) Transanal total mesorectal excision for rectal cancer: a video demonstration of rectal dissection. Dis Colon Rectum 59:157CrossRefPubMed Hasegawa S, Hida K, Kawada K, Sakai Y (2016) Transanal total mesorectal excision for rectal cancer: a video demonstration of rectal dissection. Dis Colon Rectum 59:157CrossRefPubMed
8.
Zurück zum Zitat Kawada K, Hasegawa S, Hida K, Sakai Y (2016) Advantages of the transanal approach for intersphincteric resection—a video vignette. Colorectal Dis 18:820CrossRefPubMed Kawada K, Hasegawa S, Hida K, Sakai Y (2016) Advantages of the transanal approach for intersphincteric resection—a video vignette. Colorectal Dis 18:820CrossRefPubMed
Metadaten
Titel
Transanal approach for intersphincteric resection of rectal cancer in a patient with a huge prostatic hypertrophy
verfasst von
Yoshiyuki Kiyasu
Kenji Kawada
Kyoichi Hashimoto
Ryo Takahashi
Koya Hida
Yoshiharu Sakai
Publikationsdatum
24.11.2016
Verlag
Springer Japan
Erschienen in
International Cancer Conference Journal / Ausgabe 1/2017
Elektronische ISSN: 2192-3183
DOI
https://doi.org/10.1007/s13691-016-0272-8

Weitere Artikel der Ausgabe 1/2017

International Cancer Conference Journal 1/2017 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.